GlassScriptPhysician profile
Benjamin Zimmerman Root
NPI 1619355765
$12,914.72
in general payments reported to CMS, 2019-2025
38 companies · $4,087 in 2025
The $4,087 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $210 · 2022: $1,937 · 2023: $3,031 · 2024: $3,649 · 2025: $4,087.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,656.46 |
| Education | $110.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,428.30 | 2021-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $1,678.66 | 2022-2025 | Stelara, Tremfya, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,377.52 | 2022-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $1,063.66 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $811.47 | 2022-2025 | |
| Celgene Corporation | $612.71 | 2022-2024 | Zeposia |
| Genzyme Corporation | $560.15 | 2022-2025 | |
| Lilly USA, LLC | $415.61 | 2024-2025 | Omvoh, Zepbound, Mounjaro |
| Aimmune Therapeutics, INC. | $284.25 | 2024-2025 | Vowst |
| Ardelyx, INC. | $261.03 | 2022-2025 | Ibsrela |
| Qol Medical, LLC | $252.70 | 2022-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $229.03 | 2023-2025 | Dupixent |
| Madrigal Pharmaceuticals | $207.33 | 2024-2025 | Rezdiffra, Resmetirom |
| Amgen INC. | $192.75 | 2021-2023 | Avsola, Amjevita |
| Ironwood Pharmaceuticals, INC | $190.87 | 2022-2024 | Linzess |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $178.15 | 2023-2025 | Renflexis, Hadlima |
| Intercept Pharmaceuticals, INC. | $172.64 | 2021-2025 | Ocaliva |
| Redhill Biopharma INC. | $140.28 | 2021-2023 | Movantik, Talicia |
| Gilead Sciences, INC. | $88.48 | 2025 | |
| Phathom Pharmaceuticals, INC. | $81.23 | 2024-2025 | Voquezna |
| Fresenius Kabi USA, LLC | $76.24 | 2023-2024 | Idacio |
| Merck Sharp & Dohme LLC | $74.48 | 2022-2024 | Dificid |
| Mirum Pharmaceuticals, INC. | $62.86 | 2023-2025 | Livmarli, Cholbam, Chenodal |
| Celltrion USA INC. | $54.84 | 2023-2025 | Vegzelma, Yuflyma |
| Medtronic, INC. | $49.34 | 2025 | Interstim |
| Sandoz INC. | $48.75 | 2024 | Hyrimoz |
| Braintree Laboratories, INC. | $45.28 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $45.22 | 2023 | |
| Micro-Tech Endoscopy USA, INC. | $38.90 | 2025 | Cold Snares, Buttons |
| Ferring Pharmaceuticals INC. | $31.53 | 2022 | |
| Ucb, INC. | $30.60 | 2024 | Cimzia |
| Capsovision, INC. | $27.91 | 2024 | Capsocam Plus |
| Alnylam Pharmaceuticals INC. | $27.54 | 2025 | Givlaari |
| Ipsen Biopharmaceuticals, INC | $22.38 | 2025 | Iqirvo |
| Novo Nordisk INC | $19.74 | 2025 | Wegovy |
| Sirtex Medical INC | $17.94 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $14.35 | 2024 | Andexxa |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$22,836.56 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Root listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.